BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2655961)

  • 1. A dose escalation study of carboplatin and ifosfamide in advanced ovarian cancer.
    Gallagher CJ; Wiltshaw E; Coleman RE; Harper PG
    Cancer Chemother Pharmacol; 1989; 24(1):54-7. PubMed ID: 2655961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
    Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J
    Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B; Hansen OP; Hansen HH; Hansen M
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study of cyclophosphamide plus carboplatin in advanced ovarian carcinoma.
    Edmonson JH; McCormack GW; Krook JE; Long HJ; Jefferies JA; Richardson RL
    Cancer Treat Rep; 1987 Feb; 71(2):199-200. PubMed ID: 3542210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
    Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
    Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined carboplatin plus ifosfamide and cisplatin in patients with advanced ovarian carcinoma. A phase I-II study. GOCS (Gynecological Oncology Cooperative Study).
    Lorusso V; Leone B; Di Vagno G; Manzione L; Palmeri S; Vallejo C; Machiavelli M; Nacci G; Bilancia D; Leonardi V; Catino A; Gargano G; Loverro G; Selvaggi L; De Lena M
    Gynecol Oncol; 1998 Feb; 68(2):172-7. PubMed ID: 9514802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose intensity of carboplatin in combination with cyclophosphamide or ifosfamide.
    Green JA; Smith K
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S22-5. PubMed ID: 2189593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line chemotherapy with cisplatin-ifosfamide in patients with ovarian cancer previously treated with carboplatin-cyclophosphamide.
    Polyzos A; Tsavaris N; Kosmas C; Petrikos G; Giannikos L; Kalahanis N; Papadopoulos O; Christodoulou K; Giannakopoulos K; Veslemes M; Katsilambros N
    J Chemother; 1999 Apr; 11(2):144-9. PubMed ID: 10326746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients.
    Colombo N; Speyer JL; Green M; Canetta R; Beller U; Wernz JC; Meyers M; Widman T; Blum RH; Piccart M
    Cancer Chemother Pharmacol; 1989; 23(5):323-8. PubMed ID: 2650904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined high-dose carboplatin and cisplatin, and ifosfamide in previously untreated ovarian cancer patients with residual disease.
    Lund B; Hansen M; Hansen OP; Hansen HH
    J Clin Oncol; 1990 Jul; 8(7):1226-30. PubMed ID: 2113570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study.
    Frasci G; Comella G; Comella P; Conforti S; Mastrantonio P; Zullo F; Persico G
    Gynecol Oncol; 1995 Jul; 58(1):68-73. PubMed ID: 7789893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel plus ifosfamide in advanced ovarian cancer: a multicenter phase II study.
    Miglietta L; Amoroso D; Bruzzone M; Granetto C; Catsafados E; Mammoliti S; Guarneri D; Pedulla F; Foglia G; Ragni N; Martini MC; Brema F; Addamo G; Moraglio L; Pastorino G; Boccardo F
    Oncology; 1997; 54(2):102-7. PubMed ID: 9075779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide-cisplatin versus cyclophosphamide-carboplatin in stage III-IV ovarian carcinoma: a comparison of equally myelosuppressive regimens.
    Edmonson JH; McCormack GM; Wieand HS; Kugler JW; Krook JE; Stanhope CR; Everson LK; Laurie JA; Ebbert LP; Malkasian GD
    J Natl Cancer Inst; 1989 Oct; 81(19):1500-4. PubMed ID: 2674460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.
    Perren TJ; Wiltshaw E; Harper P; Slevin M; Stein R; Tan S; Gore M; Fryatt IJ; Blake PR
    Br J Cancer; 1993 Dec; 68(6):1190-4. PubMed ID: 8260372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
    Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
    J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of carboplatin/ifosfamide in untreated advanced cervical cancer.
    Kühnle H; Meerpohl HG; Eiermann W; Röben S; Lenaz L; Achterrath W
    Cancer Chemother Pharmacol; 1990; 26 Suppl():S33-5. PubMed ID: 2189594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin combined with carboplatin: a new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma.
    Piccart MJ; Nogaret JM; Marcelis L; Longrée H; Ries F; Kains JP; Gobert P; Domange AM; Sculier JP; Gompel C
    J Natl Cancer Inst; 1990 Apr; 82(8):703-7. PubMed ID: 2181152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.
    Smith IE; Perren TJ; Ashley SA; Woodiwiss J; Forgeson GV; Yarnold JR; Ford HT
    J Clin Oncol; 1990 May; 8(5):899-905. PubMed ID: 2159056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.